{
    "clinical_study": {
        "@rank": "18588", 
        "brief_summary": {
            "textblock": "Intensive chemotherapy is associated with significant thrombocytopenia, often requiring\n      platelet transfusion to maintain platelet counts. This investigational drug has demonstrated\n      the ability to increase platelet counts. This study will test the safety and efficacy of an\n      investigational drug in the prevention of thrombocytopenia in patients with high-risk\n      sarcoma receiving AI (Adriamycin/Ifosfamide) chemotherapy."
        }, 
        "brief_title": "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Thrombocytopenia", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be newly diagnosed with moderate or high-grade sarcoma and be receiving\n             AI (Adriamycin/Ifosfamide) chemotherapy\n\n        Exclusion Criteria:\n\n          -  Patients must not have active bleeding (exclusions do apply) or history of platelet\n             disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "May 30, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038311", 
            "org_study_id": "444-ONC-0003-020"
        }, 
        "intervention": {
            "intervention_name": "PN-152,243)/PN-196,444", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 3, 2007", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=444-ONC-0003-020&StudyName=Safety+and+Efficacy+of+%28PN%2D152%2C243%29%2FPN%2D196%2C444+in+the+Prevention+of+Thrombocytopenia"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90067"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Park Ridge", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60068"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19106"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Radnor", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19087"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia Administered to Patients With High-Risk Sarcoma Receiving Intensive Chemotherapy (Adriamycin and Ifosfamide (AI))", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_outcome": {
            "measure": "To evaluate the effectiveness of intravenous rhTPO versus placebo in reducing the cumulative proportion of patients who experience severe chemotherapy induced thrombocytopenia."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038311"
        }, 
        "secondary_outcome": [
            {
                "measure": "Identify the effect of rhTPO on the number of platelet transfusions."
            }, 
            {
                "measure": "Evaluate the severity and duration of thrombocytopenia and neutropenia associated with rhTPO prophylaxis."
            }, 
            {
                "measure": "Quantify the effect of rhTPO on the occurrence of any bleeding events associated with thrombocytopenia."
            }, 
            {
                "measure": "Assess the likelihood that patients were to have adequate hematological recovery to allow on-time chemotherapy administration in the subsequent cycles."
            }, 
            {
                "measure": "Assess the safety of multiple IV doses of rhTPO."
            }, 
            {
                "measure": "Determine the occurrence and clinical implications of any anti-TPO antibodies."
            }, 
            {
                "measure": "Assess the antitumor activity of AI chemotherapy."
            }, 
            {
                "measure": "Evaluate the impact of rhTPO prophylaxis on health economics/cost effectiveness."
            }, 
            {
                "measure": "Evaluate the impact of rhTPO prophylaxis on patient quality of life."
            }, 
            {
                "measure": "\uf020Determine serum concentrations of TPO in the context of rhTPO and chemotherapy administration"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2006"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "29.76 -95.369"
    }
}